Lenalidomide enhances the function of dendritic cells generated from patients with multiple myeloma

Experimental Hematology

Volumn 46, Issue , 2017, Pages 48-55

  Vo, Manh Cuong ^a   Anh NguyenThi, Truc ^a   Lee, Hyun Ju ^a   Nguyen Pham, Thanh Nhan ^a   Jaya Lakshmi, Thangaraj ^a   Jung, Sung Hoon ^a   Kim, Hyeoung Joon ^a   Lee, Je Jung ^a  

^a Chonnam National University Research Institute of Medical Sciences   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12P70; LENALIDOMIDE; BIOLOGICAL MARKER; CYTOKINE; IMMUNOLOGIC FACTOR; THALIDOMIDE;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL POLARITY; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECT; ENDOCYTOSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE COUNT; MONOCYTE; MULTIPLE MYELOMA; POLARIZATION; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TH1 CELL; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOPHENOTYPING; METABOLISM; PHENOTYPE; T LYMPHOCYTE SUBPOPULATION;

BIOMARKERS; CELL SURVIVAL; CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; IMMUNOPHENOTYPING; MULTIPLE MYELOMA; PHENOTYPE; T-LYMPHOCYTE SUBSETS; THALIDOMIDE;

EID: 85008512129     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.11.004     Document Type: Article

References (35)

1. 1 Kumar, S.K., Gertz, M.A., Risk adapted therapy for multiple myeloma: Back to basics. Leuk Lymphoma 55 (2014), 2219–2220.
2. 2 Balakumaran, A., Robey, P.G., Fedarko, N., Landgren, O., Bone marrow microenvironment in myelomagenesis: Its potential role in early diagnosis. Expert Rev Mol Diagn 10 (2010), 465–480.
3. 3 Raje, N., Hideshima, T., Davies, F.E., et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol 125 (2004), 343–352.
4. 4 Lee, J.J., Choi, B.H., Kang, H.K., et al. Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma 48 (2007), 2022–2031.
5. 5 Mayordomo, J.I., Zorina, T., Storkus, W.J., et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1 (1995), 1297–1302.
6. 6 Wen, Y.J., Ling, M., Bailey-Wood, R., Lim, S.H., Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clin Cancer Res 4 (1998), 957–962.
7. 7 Röllig, C., Schmidt, C., Bornhäuser, M., Ehninger, G., Schmitz, M., Auffermann-Gretzinger, S., Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. J Immunother 34 (2011), 100–106.
8. 8 Nguyen-Pham, T.N., Lee, Y.K., Kim, H.J., Lee, J.J., Immunotherapy using dendritic cells against multiple myeloma: How to improve?. Clin Dev Immunol, 2012, 2012, 397648.
9. 9 Ratta, M., Fagnoni, F., Curti, A., et al. Dendritic cells are functionally defective in multiple myeloma: The role of interleukin-6. Blood 100 (2002), 230–237.
10. 10 Christopher, P., Gina, B.S., Gordon, C., Immune dysfuction in multiple myeloma. Int J Hematol Oncol 2 (2013), 49–59.
11. 11 Dimopoulos, M., Spencer, A., Attal, M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357 (2007), 2123–2132.
12. 12 Weber, D.M., Chen, C., Niesvizky, R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357 (2007), 2133–2142.
13. 13 Davies, F.E., Raje, N., Hideshima, T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001), 210–216.
14. 14 Kotla, V., Goel, S., Nischal, S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol, 2, 2009, 36.
15. 15 Dauguet, N., Fournié, J.J., Poupot, R., Poupot, M., Lenalidomide down regulates the production of interferon-gamma and the expression of inhibitory cytotoxic receptors of human natural killer cells. Cell Immunol 264 (2010), 163–170.
16. 16 Galustian, C., Dalgleish, A., Lenalidomide: A novel anticancer drug with multiple modalities. Expert Opin Pharmacother 10 (2009), 125–133.
17. 17 Galustian, C., Meyer, B., Labarthe, M.C., et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 58 (2009), 1033–1045.
18. 18 Dimopoulos, M.A., Chen, C., Spencer, A., et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 23 (2009), 2147–2152.
19. 19 Palumbo, A., Hajek, R., Delforge, M., et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366 (2012), 1759–1769.
20. 20 Lagrue, K., Carisey, A., Morgan, D.J., Chopra, R., Davis, D.M., Lenalidomide augments actin remodelling and lowers NK cell activation thresholds. Blood 126 (2015), 50–60.
21. 21 Qiao, S.K., Guo, X.N., Ren, J.H., Ren, H.Y., Efficacy and safety of lenalidomide in the treatment of multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Chin Med J (Engl) 128 (2015), 1215–1222.
22. 22 Luptakova, K., Brett, G., Heidi, M., et al. Lenalidomide decreases PD-1 expression, depletes regulatory T-cells and improves cellular response to a multiple myeloma/dendritic cell fusion vaccine in vitro. Abstract presented at 53rd ASH Annual Meeting and Exposition. Blood, 116, 2010 Abstract 492.
23. 23 Luptakova, K., Rosenblatt, J., Glotzbecker, B., et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 62 (2013), 39–49.
24. 24 Nguyen-Pham, T.N., Jung, S.H., Vo, M.C., et al. lenalidomide synergistically enhances the effect of dendritic cell vaccination in a model of murine multiple myeloma. J Immunother 38 (2015), 330–339.
25. 25 Hirai, M., Kadowaki, N., Kitawaki, T., et al. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 117 (2011), 500–509.
26. 26 Wang, Y., Liang, Y., Zhang, Y., Wu, D., Liu, H., Bortezomib inhibits bone marrow-derived dendritic cells. Int J Clin Exp Pathol 8 (2015), 4857–4862.
27. 27 Liu, W.M., Henry, J.Y., Meyer, B., Bartlett, J.B., Dalgleish, A.G., Galustian, C., Inhibition of metastatic potential in colorectal carcinoma in vivo and in vitro using immunomodulatory drugs (IMiDs). Br J Cancer 101 (2009), 803–812.
28. 28 Liu, W.M., Laux, H., Henry, J.Y., Bolton, T.B., Dalgleish, A.G., Galustian, C., A microarray study of altered gene expression in colorectal cancer cells after treatment with immunomodulatory drugs: Differences in action in vivo and in vitro. Mol Biol Rep 37 (2010), 1801–1814.
29. 29 Henry, J.Y., Lu, L., Adams, M., et al. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo. Prostate 72 (2012), 856–867.
30. 30 Lopez-Girona, A., Heintel, D., Zhang, H., et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 154 (2011), 325–336.
31. 31 Maïga, S., Gomez-Bouqie, P., Bonnaud, S., et al. Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma. Br J Cancer 108 (2013), 1801–1806.
32. + T cells in vitro. J Infect Dis 187 (2003), 946–955.
33. + T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide. Immunology 139 (2013), 377–385.
34. 34 Balasa, B., Yun, R., Belmar, N.A., et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol Immunother 64 (2015), 61–73.
35. 35 Lonial, S., Dimopoulos, M., Palumbo, A., et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373 (2015), 621–631.